DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
DMX-1001 (oral noribogaine) is a novel neuroplastogen therapeutic that combines neuroplasticity and polypharmacology for the treatment of AUD AUD affects more than 29 million Americans and is a leading cause of preventable death; about 60 percent of patients treated for AUD relapse to hazardous drinking within six months Successful completion of the planned alcohol interaction … [Read more…]
